Servier Group notes Egis board announcement

Hungarian version

Suresnes, France, October 1, 2013 – Arts et Techniques du Progrès (“ATP”), the wholly owned subsidiary of the Servier Group that announced on September 24, 2013 a Voluntary Public Purchase Offer (“The Offer”) for the shares in Egis Pharmaceuticals plc (“Egis” or the “Company”) it does not currently own, notes the announcement earlier today from Egis.  Its Board of Directors have reviewed the Offer, which at HUF28,000 per share represents a premium of 33% over the closing price of Egis shares on September 23, 2013 the last trading day preceding the announcement of the Offer, and a premium of 38% over the average trading price of Egis shares over the six months ended September 23, 2013. 

ATP notes the opinion of the Board of Directors of Egis, that the Offer can be considered to be fair for the Company.  In addition, the Board of Directors noted that, while the decision to accept or refuse the Offer is for each individual shareholder based on its own or its advisors’ analysis of the Offer including specific financial considerations such as taxation which the Board of Directors cannot consider for individuals, the Offer can be considered fair for a significant number of shareholders.  A full copy of the opinion of the Board of Directors of Egis is available on the Egis website,, as well as,, and

Following the approval of the Offer by the Hungarian Financial Supervisory Authority on Friday September 27, 2013 the Offer will commence on October 2, 2013 and be open until November 5, 2013 when it will close.  The process of cash payment to each shareholder accepting the Offer will be initiated no later than November 12, 2013.

As announced previously, the Offer is final and will not be increased or repeated following its closing.  Following the conclusion of the Offer, ATP will consider requesting a general meeting of Egis to decide on the delisting of Egis from the Budapest Stock Exchange.

Shareholders who wish to accept the Offer should visit For any additional information on the Offer, visit,,,,
An interview with Pascal Touchon, Director of Business Development of Servier Group, is available on Servier Group’s website or on

Background information

About Servier Group
Servier Group is a privately-held research-led pharmaceutical group, with more than 20,000 employees, including 3,000 in R&D, around the world and with its products available in more than 140 countries. Organized as a foundation and deeply committed to research, it reinvests a large portion of its turnover in the research and development of innovative medications.
About Egis
Egis, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe and CIS countries. The company focuses on research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in many countries across the world through business partners and strong subsidiary companies network.

Media Contacts
Jon Coles     
Brunswick Group   
Tel: +44 20 7404 5959   

Pip Green  
Brunswick Group
Tel: +44 20 7404 5959

In Budapest:
Imre Varga   
Noguchi Porter Novelli    
Tel: +36 30 433 9092   

Balazs Szanto
Noguchi Porter Novelli
Tel: +36 30 934 5362

Investor Contacts
KBC Securities Hungary provides assistance concerning the acceptance of the Offer and the submission of the related shareholder declarations:
Tel: +36 1 483-4088
Fax: +36 1 483-4089

Ádám Hegyi   
KBC Securities Hungary    
Tel: +36 1 483 4086  

Miklós Bónis
KBC Securities Hungary
Tel: +36 1 483 4083